Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 3.54M
Average 0.45M
IVA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Inventiva S.A.NASDAQ: IVA
Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025
Selling, general & admin grows 317.9% year over year
Q4 FY2025 selling, general & admin of €37.27M rose 317.9% year over year. Over 3 fiscal years it compounded at +51.5% a year.
Context
- Selling, general & admin amounted to 1202.1% of revenue in FY2025, up 1016.2 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of €13.83M (-74.3%) for the fiscal year ending Dec 2026, a slowdown from the +215.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- €37.27M— QoQ
- Last fiscal yearDec 2025
- €53.89M+215.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
EUR · from the income statement
- Latest · FY2025
- 53.89M EUR
- Year-over-year change
- +215.2%
- 4-year CAGR
- +47.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 53.89M | +215.2% |
| FY2024 | 2024-12-31 | 17.1M | +9.6% |
| FY2023 | 2023-12-31 | 15.61M | +0.7% |
| FY2022 | 2022-12-31 | 15.5M | +34.5% |
| FY2021 | 2021-12-31 | 11.52M | — |
Selling, General & Admin vs competitors
How IVA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +215.2% is the highest of 10, against a peer median of +4.4%.
- Selling, general & admin amounts to 1202.1% of revenue for IVA, versus a peer median of 323.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.78M USD | +14.7% | +12.5% | 133.9% | |
| FY2025 | €53.89M EUR | +215.2% | +51.5% | 1202.1% | |
| LTM Mar 2026 | $38.28M USD | -25.4% | -1.1% | 55.3% | |
| LTM Mar 2026 | $36.25M USD | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $30.27M USD | +4.4% | +9.7% | 1705.2% | |
| LTM Mar 2026 | $26.99M USD | +11.1% | +24.6% | 82.5% | |
| LTM Mar 2026 | $24.19M USD | +23.5% | +3.4% | 41000.0% | |
| LTM Mar 2026 | $23.71M USD | -4.5% | +3.4% | 10537.3% | |
| LTM Mar 2026 | $23.69M USD | +2.7% | +2.7% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $17.83M USD | +52.6% | +62.5% | — |
| Peer median (excluding IVA) | — | +4.4% | +3.4% | 323.5% | |
Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.19M | 12.18M | 17.48M | 9.2M | 4.48M |
| Cost of Revenue | 1.02M | 995K | (23K) | 3.88M | 2.8M |
| Gross Profit | 4.19M | 17.06M | 17.5M | 9.2M | 1.51M |
| Gross Margin | 100.0% | 140.1% | 100.1% | 100.0% | 33.7% |
| Research & Development | 48.45M | 60.47M | 110.01M | 90.88M | 83.61M |
| Selling, General & Admin | 11.52M | 15.5M | 15.61M | 17.1M | 53.89M |
| Operating Expenses | 56.31M | 74.17M | 120.19M | 106.76M | 137.37M |
| Depreciation & Amortization | 858K | 870K | 2.6M | 5.2M | 2.8M |
| EBITDA | (52.76M) | (56.29M) | (102.04M) | (166.53M) | (128.15M) |
| EBITDA Margin | -1258.0% | -462.2% | -583.9% | -1810.4% | -2858.6% |
| Operating Income | (52.11M) | (57.11M) | (102.71M) | (97.56M) | (130.95M) |
| Operating Margin | -1242.6% | -468.9% | -587.7% | -1060.6% | -2921.0% |
| Interest Income | 57K | 390K | 945K | 1.14M | 2.83M |
| Interest Expense | 138K | 707K | 5.18M | 12.18M | 32.3M |
| Other Income / Expenses | 2.84M | 2.82M | (7.11M) | (86.34M) | (211.38M) |
| Income Before Tax | (49.27M) | (54.29M) | (109.82M) | (183.9M) | (342.33M) |
| Pre-Tax Margin | -1174.8% | -445.8% | -628.4% | -1999.4% | -7636.1% |
| Income Tax Expense | 364K | (20K) | 607K | 313K | 22K |
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Net Margin | -1183.5% | -445.6% | -631.8% | -2002.7% | -7587.8% |
| EPS (Basic) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| EPS (Diluted) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| Weighted Avg Shares | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
| Weighted Avg Shares (Diluted) | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.